by Plus Therapeutics | Apr 3, 2024 | GBM
Plus Therapeutics’ novel approach to treating Glioblastoma overcomes the limitations of all three currently employed treatment modalities. Leveraging established, targeted delivery techniques, we seek to inject high doses of radiation directly into or near a...
by Plus Therapeutics | Apr 2, 2024 | Uncategorized
We are pleased to introduce Frank Gonzalez Rodriguez as Senior Clinical Trial Associate at Plus Therapeutics! He is looking forward to being on the sponsor side of our clinical trials and part of our clinical operations team....
by Plus Therapeutics | Apr 1, 2024 | Uncategorized
April is dedicated to raising awareness for cancer prevention and treatment throughout the US. 🎗️ At Plus Therapeutics, we seek to help patients and clinicians find safe, lasting solutions for treating rare and difficult-to-treat cancers....
by Plus Therapeutics | Mar 30, 2024 | Uncategorized
We want to thank all of the #doctors and Principal Investigators we get to work with to help us run our #clinicaltrials and provide #treatment options for #patients! They all are great supporters of our mission to solve the toughest challenges in #oncology 🩺...
by Plus Therapeutics | Mar 28, 2024 | LM
In case you missed it, we announced the validation & clinical implementation of our CSF-01 Leptomeningeal Cancer Cell Diagnostic. The CSF-01 cancer cell enumeration test is an exploratory endpoint in the ReSPECT-LM Phase 1 trial that has shown promise in the...
Recent Comments